Biopharma company GW Pharma has named Julian Gangolli as its president for North America.
GW Pharma is also relocating its CEO, Justin Glover, to the US to support its imminent launch in the States.
Commenting on his appointment, Gangolli said: “I wish to bring my experience of building a successful business for Allergan to GW and look forward to working with Justin and the entire GW team to optimise the Company’s prospects in this key market.”
Gangolli was president of the North American pharma division of Allergan for from 2004 until April of this year, overseeing a 1,400 person commercial operation.
As president, Gangolli’s responsibilities included four business units supporting ophthalmology and optometry, neurosciences, urology and medical dermatology for the US and Canada.
He was additionally responsible for strategic planning, business development, research and product development planning for the North American division.
Geoffrey Guy, GW Pharma’s chairman, added: “Julian’s deep experience at building and running a major US pharmaceutical business built on specialty products will be complemented by the relocation of Justin to the US with his intimate knowledge of GW, its products and pipeline.
“Together, they will spearhead GW’s growth in the U.S. and help to bring much needed new treatments to patients.”